ASTEROID Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ASTEROID Trial On the Web |
|
American Roentgen Ray Society Images of ASTEROID Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for ASTEROID Trial.
ASTEROID Trial
Objective
To assess if an extensive lipid lowering therapy with statins could regress coronary atherosclerosis as determined by IVUS imaging.
Methods
A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) was a prospective open-label blinded end-points trial wherein 507 patients, who had a baseline IVUS examination, received at least 1 dose of the study drug rosuvastatin 40 mg/dL and were followed up for 24 months. At the end of 24 months 349 patients had evaluable serial IVUS examinations.
Results
Mean baseline LDL-C reduced by 53.2% and mean HDL-C improved by 14.7%. Also mean atheroma volume for the entire vessel, as assessed by intravascular ultrasound, reduced by 0.98%.
Conclusion
The study showed that treatment with very high intensity statin therapy using rosuvastatin 40 mg/dL reduced LDL-C and improved HDL-C levels significantly resulting in regression of coronary atherosclerosis as measured by IVUS.[1]